Canon U.S.A. Announces Strategic Investment In Spartan Bioscience

Canon U.S.A. Announces Strategic Investment In Spartan Bioscience

Canon U.S.A. Announces Strategic Investment In Spartan Bioscience

The FIANNCIAL -- Canon U.S.A., Inc., one of the leaders in digital imaging solutions, on March 18 announced that it has made a strategic investment in Spartan Bioscience Inc., one of the leaders in on-demand DNA testing, to help fund the research and development of new diagnostic testing products.

Canon BioMedical, Inc., the recently established wholly- owned subsidiary of Canon U.S.A., Inc., plans to explore areas to work with Spartan on the development of future diagnostic products, including rapid genetic testing.

"Canon is excited to work with Spartan Bioscience Inc., on developing breakthrough technologies in the area of genetic testing," said Seymour Liebman, executive vice president, chief administrative officer and general counsel, Canon U.S.A., Inc. "Spartan's goals align with our mission to provide enhanced diagnostic testing systems that can help improve human health worldwide."

"We are excited to continue our efforts as we move into new markets for rapid genetic testing," said Paul Lem, M.D., CEO of Spartan Bioscience Inc. "Working with Canon will help accelerate our progress in the future."

Seymour Liebman, member of the Board of Directors of Canon BioMedical, Inc., will join the Board of Directors of Spartan Bioscience.